OUR MISSION

Our mission is to bring novel treatment options to rare kidney diseases and to partner closely with the medical and patient communities we serve. The first step in this journey is to protect the kidney from the deleterious effects of inappropriately high oxalate concentrations.

homepage-primary-hyperoxaluria

Primary Hyperoxaluria

A devastating ultra-orphan genetic disease that is usually diagnosed when patients are quite young

It results in the over production and over accumulation of oxalate, causing progressive kidney damage and deposition of calcium-oxalate crystals throughout the body.

Pipeline

Utilizing special features as an activated bimodal enteric biotherapy, Oxabact could provide the first orally derived solution to tackle primary hyperoxaluria by promoting active secretion of oxalate from plasma into the gut and degrading it there. This enteric elimination in turn reduces the high oxalate burden on the kidneys.

homepage-pipeline-photo
homepage-the-team-photo

The Team

OxThera is built on a highly-experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing. We are supported by an experienced and dedicated group of life science investors.

Our Medical Partner Networks

The American Society of Nephrology (ASN)
KHI’s mission is to advance scientific understanding of the kidney health and patient safety implications of new and existing medical products and to foster development of therapies for diseases that affect the kidney by creating a collaborative environment in which FDA and the greater nephrology community can interact to optimize evaluation of drugs, devices, biologics, and food products.

The Oxalosis and Hyperoxaluria Foundation (OHF)
The Oxalosis and Hyperoxaluria Foundation (OHF) is the leading organization in the world dedicated to the awareness, understanding and treatment of Primary Hyperoxaluria, Oxalosis and related Hyperoxaluria Kidney Stone Conditions for thousands of healthcare professionals, patients and their families. We aim to share our knowledge so that everyone – patients, medical professionals, government officials, the general public and industry has accurate information about the advances in our disease.